References
[1] Tasian SK, Hunger SP. Genomic characterization of paediatric acute lymphoblastic leukaemia: an opportunity for precision medicine therapeutics. Br J Haematol. 2017;176:867-82.
[2] Tang J, Yu J, Cai J, Zhang L, Hu S, Gao J, et al. Prognostic factors for CNS control in children with acute lymphoblastic leukemia treated without cranial irradiation. Blood. 2021;138:331-43.
[3] Xue Yujuan, Lu Aidong, Wu Jun, Zuo Yingxi, Jia Yueping, Zhang Leping. Molecular response and prognosis of pediatric patients with Ph-positive acute lymphoblastic leukemia treated by tyrosine kinase inhibitors with chemotherapy. Chin J Appl Clin Pediatr. 2020;35:201-5.
[4] Shen S, Chen X, Cai J, Yu J, Gao J, Hu S, et al. Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA Oncol. 2020;6:358-66.
[5] WANG Liang, XU Jing, CHEN Fa-dong. A case of reversible pulmonary arterial hypertension caused bydasatinib and analysis of clinical features. Fudan University Journal of Medical Sciences. 2022;49:469-74.
[6] Haematology Group of Pediatrics Branch of Chinese Medical Association,Editorial Board of the Chinese Journal of Pediatrics. Recommendations for the treatment of acute lymphoblastic leukemia in children (fourth revision). Chinese Journal of Pediatrics. 2014;52:641-4.
[7] Kato M, Manabe A. Treatment and biology of pediatric acute lymphoblastic leukemia. Pediatr Int. 2018;60:4-12.
[8] Ibrahim U, Saqib A, Dhar V, Odaimi M. Dasatinib-induced pulmonary arterial hypertension - A rare late complication. J Oncol Pharm Pract. 2019;25:727-30.
[9] Jose A, Rafei H, Ahari J. Combination targeted pulmonary hypertension therapy in the resolution of Dasatinib-associated pulmonary arterial hypertension. Pulm Circ. 2017;7:4 803-7.
[10] Walid R. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leukemia research. 2009;33:861-4.
[11] Mattei D,Feola M, Orzan F, Mordini N, Rapezzi D, Gallamini A. Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant. 2009;43:967-8.
[12] Hennigs JK, Keller G, Baumann HJ, Honecker F, Kluge S, Bokemeyer C, Brümmendorf TH, Klose H. Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension? BMC Pulm Med. 2011;11:30.
[13] Orlandi EM, Rocca B, Pazzano AS, Ghio S. Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia. Leuk Res. 2012;36:e4-6.
[14] Dumitrescu D, Seck C, ten Freyhaus H, Gerhardt F, Erdmann E, Rosenkranz S. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia. Eur Respir J. 2011;38: 218-20.
[15] Sano M, Saotome M, Urushida T, Katoh H, Satoh H, Ohnishi K, et al. Pulmonary arterial hypertension caused by treatment with dasatinib for chronic myeloid leukemia -critical alert. Intern Med. 2012;51:2337-40.
[16] Groeneveldt JA, Gans SJ, Bogaard HJ, Vonk-Noordegraaf A. Dasatinib-induced pulmonary arterial hypertension unresponsive to PDE-5 inhibition. Eur Respir J. 2013;42:869-70.
[17] Liu Bingcheng W Y, Mi Yingchang, Wang Jianxiang. Reversible pulmonary arterial hypertension related to dasatinib in the treatment for chronic myelogenous leukemia: a case report and literature review. Chin J Hematol. 2014;35:581-6.
[18] Liu Bingcheng, Wang Ying, Mi Yingchang, Wang Jianxiang. Reversible dasatinib-related pulmonary arterial hypertension diagnosed by noninvasive echocardiography. Kaohsiung J Med Sci. 2015;31:165-6.
[19] Buchelli Ramirez HL, Álvarez Álvarez CM, Rodríguez Reguero JJ, García Clemente MM, Casan Clarà P. Reversible pre-capillary pulmonary hypertension due to dasatinib. Respir Care. 2014;59:e77-80.
[20] Hong JH, Lee SE, Choi SY, Kim SH, Jang EJ, Bang JH,et al. Reversible Pulmonary Arterial Hypertension Associated with Dasatinib for Chronic Myeloid Leukemia. Cancer Res Treat. 2015;47:937-42.
[21] Jin Jin, Xu Xiaomao, Wang Chen. Repeated partially reversible pulmonary arterial hypertension related to dasatinib: a case report and literature review. Chin J Tuberc Respir Dis. 2016;39:83-7.
[22] Seegobin K, Babbar A, Ferreira J, Lyons B, Cury J, Seeram V. A case of worsening pulmonary arterial hypertension and pleural effusions by bosutinib after prior treatment with dasatinib. Pulm Circ. 2017;7: 808-12.
[23] Skride A, Sablinskis M, Sablinskis K, Lesina K, Lejnieks A, Lejniece S. Pulmonary arterial hypertension in a patient treated with dasatinib: a case report. J Med Case Rep. 2017;11:362.
[24] Nishimori M, Honjo T, Kaihotsu K, Sone N, Yoshikawa S, Imanishi J, et al. Dasatinib-Induced Pulmonary Arterial Hypertension Treated with Upfront Combination Therapy. Case Rep Cardiol. 2018;2018:3895197.
[25] Zhao Yangyang, Qike Cao, Yunshan Yan, Xiaojing, Fu Yuan, Chen Yang, et al. A case of pulmonary hypertension due to dasatinib confirmed by right heart catheterization and review of the literature. Journal of Lanzhou University(Medical Sciences). 2018;44:31-6.
[26] Toya T, Nagatomo Y, Kagami K, Adachi T. Dasatinib-induced pulmonary arterial hypertension complicated with scleroderma: a case report. Eur Heart J Case Rep. 2019;3: ytz025.
[27] Orlikow E, Weatherald J, Hirani N. Dasatinib-Induced Pulmonary Arterial Hypertension. Can J Cardiol. 2019;35:1604 e1- e3.
[28] Duvvuri PD, Liu J, Bhardwaj C.  A 59-Year-Old Woman With Shortness of Breath and Chest Pain. Chest. 2020;158:e65-e9.
[29] Zeng Qixian, Luo Qin, Zhao Zhihui, Zhao Qing, Liu Zhihong, Xiong Changming. Dasatinib induces pulmonary arterial hypertension: A case report. China Clinical Case Results Database, 2022;4:e642.
[30] Kim JC, Shin SH, Yi HG, Kim SH, Woo SI, Kim DH, et al. Rapid-onset pulmonary arterial hypertension in a patient with acute lymphoblastic leukemia treated with dasatinib. Herz. 2013;38:931-3.
[31] Taçoy G, Çengel A, Özkurt ZN, Türkoğlu S. Dasatinib-induced pulmonary hypertension in acute lymphoblastic leukemia: case report. Turk Kardiyol Dern Ars. 2015;43:78-81.
[32] Li Ji, Zhao Huihui, Li Yanru, Zhu Yu, Lu Ruinan, Zhang Xiaoyan, et al. Dasatinib cuses reversible pulmonary hypertension, pleural effusion, pericardial effusion and literature review in a case of Ph-positive acute lymphoblastic leukemia. Journal of Nanjing Medical University (Natural Science Edition). 2016;3:764-8.